[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552063":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":24,"locations":24,"responsibleParty":25,"collaborators":24,"id":29,"slug":24,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":32,"acronym":24,"eligibilityCriteria":33,"healthyVolunteers":30,"sex":34,"minAge":24,"maxAge":35,"enrollmentInfo":36,"targetDuration":24,"studyType":39,"phases":40,"briefSummary":42,"conditions":43,"keywords":46,"overallStatus":50,"whyStopped":24,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":24},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Study on Fertility Sparing Therapy in IA Stage G2 Endometrial Cancer Patients","EXPERIMENTAL","Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg\u002Fd or MA 320mg\u002Fd.",[13],"Drug: Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg\u002Fd or MA 320mg\u002Fd.",{"label":15,"type":10,"description":16,"interventionNames":17},"The Study on Fertility Sparing Therapy in IA Stage G2 Endometrial Cancer Patients","Treatment Option 2 is a combination therapy, consisting of oral MPA 500mg\u002Fd\u002FMA 320mg\u002Fd combined with the intrauterine insertion of the levonorgestrel intrauterine system (LNG-IUS, Mirena IUD).",[13],[19],{"type":20,"name":11,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Compare the efficacy of mono-therapy with progesterone versus combined therapy to determine the best treatment option.",[9,15],[16],null,{"type":26,"investigatorFullName":27,"investigatorTitle":28,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Wang Jianliu","Deaprtment of Obstetrics and Gynecology","100552063",false,"NCT06468215","Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer","Inclusion Criteria:\n\n* Endometrioid adenocarcinoma G2, diagnosis by pathological.\n* The lesion is limited to the endometrium.\n* FIGO (2009) staging is IA.\n* Age less than 45.\n* Strongly request to preserve fertility.\n* Sign informed consent.\n\nExclusion Criteria:\n\n* The tumor has invaded the muscle layer.\n* FIGO (2009) stage IB or higher.\n* Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer\n* There are malignant tumors in other systems.\n* Have contraindications for conservative treatment or drug use.\n* Have been judged by the researcher to be unsuitable for childbearing.","FEMALE","45 Years",{"count":37,"type":38},16,"ESTIMATED","INTERVENTIONAL",[41],"NA","Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.",[44,45],"Carcinoma, Endometrioid","Fertility Preservation",[47,48,49],"endometrial cancer","fertility-sparing treatment","grade 2","NOT_YET_RECRUITING","2024-07-13",{"date":53,"type":54},"2024-07-16","ACTUAL",{"date":56,"type":38},"2024-07",{"date":58,"type":38},"2028-10",{"name":5,"class":6}]